COHANCE LIFESCIENCES LTD COHANCE NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.cohance.com

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.

Market & Price

Market Cap

₹16,523.54 Cr

Current Price

₹431.50

High / Low (52W)

₹1,097.00 / ₹279.90

Beta

0.65

Valuation

Stock P/E

92.60

Industry PE

37.60

Forward P/E

33.54

PEG Ratio

Book Value

₹102.03

Price to Book

4.23

P/S

7.28

EV/EBITDA

39.20

Dividend Yield

Profitability & Returns

ROCE

4.81%

ROE

3.84%

ROA

2.67%

Profit Margin

7.90%

Op Margin

7.66%

EPS (Latest Qtr)

₹0.50

EPS (TTM)

₹4.66

Balance Sheet & Liquidity

Debt/Equity

0.10

Quick Ratio

1.56

Current Ratio

2.83

Debt

₹400.49 Cr

Total Assets

₹5,729.64 Cr

Current Assets

₹1,827.96 Cr

Working Capital

₹1,182.03 Cr

Ownership

Promoter Holding

63.97%

Chg in Prom Hold

FII / Inst Holding

24.76%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹16,737.88 Cr

Total Revenue (TTM)

₹2,268.55 Cr

EBITDA

₹426.99 Cr

Free Cash Flow

₹48.57 Cr

Operating Cash Flow

₹368.32 Cr

Shares Outstanding

₹38.26 Cr

Gross Margin

70.79%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

19.45%

Profit 5Y

-24.19%

Revenue (YoY)

-26.30%

Earnings (YoY)

-89.00%

PROS

Compounding revenue at 19.4% over 5 years.
Generates positive free cash flow.

CONS

Trading at a high P/E of 92.6.
Earnings shrank at -24.2% CAGR over 5 years.
Trading 60.7% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	COHANCE COHANCE LIFESCIENCES LTD NIFTY_SMALLNSEPHARMA	431.50	92.60	₹16,523.54 Cr	-	4.81%	3.84%	19.45%	-24.19%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	840.42 Cr	549.31 Cr	555.57 Cr	544.55 Cr	619.12 Cr
Cost of Revenue	-	300.02 Cr	148.14 Cr	141.13 Cr	158.91 Cr	214.45 Cr
Gross Profit	-	540.40 Cr	401.17 Cr	414.44 Cr	385.64 Cr	404.67 Cr
Operating Expenses	-	365.35 Cr	334.30 Cr	337.51 Cr	337.23 Cr	357.22 Cr
Operating Income	-	175.05 Cr	66.87 Cr	76.93 Cr	48.41 Cr	47.45 Cr
EBITDA	-	225.49 Cr	118.08 Cr	136.55 Cr	96.65 Cr	80.33 Cr
Interest Expense	-	10.45 Cr	10.18 Cr	8.76 Cr	9.11 Cr	9.19 Cr
Pretax Income	-	160.87 Cr	62.76 Cr	83.77 Cr	40.60 Cr	19.91 Cr
Tax Provision	-	43.72 Cr	16.36 Cr	17.38 Cr	11.58 Cr	11.60 Cr
Net Income	-	120.43 Cr	48.82 Cr	74.08 Cr	36.72 Cr	19.55 Cr
Diluted EPS	-	3.10	1.27	1.92	0.96	0.50

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	1,331.11 Cr	1,034.06 Cr	2,608.50 Cr	2,268.55 Cr
Cost of Revenue	-	586.19 Cr	317.85 Cr	816.48 Cr	662.63 Cr
Gross Profit	-	744.92 Cr	716.21 Cr	1,792.02 Cr	1,605.92 Cr
Operating Expenses	-	218.61 Cr	361.81 Cr	1,161.76 Cr	1,366.26 Cr
Operating Income	-	526.30 Cr	354.40 Cr	630.26 Cr	239.66 Cr
EBITDA	-	620.53 Cr	467.22 Cr	850.49 Cr	431.61 Cr
Interest Expense	-	12.81 Cr	6.95 Cr	41.06 Cr	37.24 Cr
Pretax Income	-	559.73 Cr	405.67 Cr	642.63 Cr	207.04 Cr
Tax Provision	-	148.44 Cr	105.39 Cr	158.39 Cr	56.92 Cr
Net Income	-	411.29 Cr	300.28 Cr	487.34 Cr	179.23 Cr
Diluted EPS	-	16.16	11.80	12.68	4.68

Compounded Sales Growth

5 Years:	19.45%
1 Year:	-26.30%

Compounded Profit Growth

5 Years:	-24.19%
1 Year:	-89.00%

Stock Price Performance

1 Year:	-59.54%
6 Months:	-23.06%
3 Months:	+39.40%
1 Month:	-10.71%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	1,965.74 Cr	2,254.91 Cr	3,031.75 Cr	5,729.64 Cr
Current Assets	-	1,011.05 Cr	1,252.78 Cr	888.59 Cr	1,827.96 Cr
Cash & Equivalents	-	64.80 Cr	47.23 Cr	85.40 Cr	49.14 Cr
Inventory	-	312.81 Cr	231.20 Cr	166.57 Cr	562.23 Cr
Receivables	-	110.94 Cr	133.66 Cr	284.44 Cr	681.01 Cr
Total Liabilities	-	230.56 Cr	204.24 Cr	1,191.11 Cr	1,695.81 Cr
Current Liabilities	-	158.77 Cr	117.40 Cr	365.19 Cr	645.93 Cr
Long Term Debt	-	4.56 Cr	0	6.24 Cr	50.48 Cr
Total Debt	-	70.34 Cr	65.01 Cr	279.07 Cr	400.49 Cr
Total Equity	-	1,735.18 Cr	2,050.67 Cr	1,696.58 Cr	3,911.29 Cr
Shares Outstanding	-	25.46 Cr	25.46 Cr	25.46 Cr	38.26 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	457.20 Cr	384.77 Cr	673.35 Cr	368.32 Cr
Investing Cash Flow	-	-195.01 Cr	-362.35 Cr	-389.70 Cr	-254.57 Cr
Financing Cash Flow	-	-241.95 Cr	-39.99 Cr	-327.40 Cr	-165.15 Cr
Capital Expenditure	-	-285.91 Cr	-51.88 Cr	-316.80 Cr	-219.88 Cr
Free Cash Flow	-	171.28 Cr	332.89 Cr	356.55 Cr	148.44 Cr
Net Change in Cash	-	20.24 Cr	-17.57 Cr	-43.75 Cr	-51.40 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	56.0%	69.3%	68.7%	70.8%
Operating Margin %	-	39.5%	34.3%	24.2%	10.6%
Net Margin %	-	30.9%	29.0%	18.7%	7.9%
ROE %	-	23.7%	14.6%	28.7%	4.6%
ROCE %	-	29.1%	16.6%	23.6%	4.7%

Shareholding Pattern

Insiders

63.97%

Institutions

24.76%

Public Float

68.71%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for COHANCE

No recent headlines available.

COHANCE · Healthcare